Konvulex solution 5100mg / ml, No. 5
Expiration Date: 05/2027
Russian Pharmacy name:
Конвулекс раствор 5100мг/мл, №5
status epilepticus;
epilepsy of various etiologies - idiopathic, cryptogenic and symptomatic;
generalized epileptic seizures in adults and children: clonic, tonic, tonic-clonic, absences, myoclonic, atonic;
partial epileptic seizures in adults and children: with or without secondary generalization;
specific syndromes (Vesta, Lennox-Gastaut);
febrile seizures in children;
treatment and prevention of bipolar disorder.
In / in. With intravenous slow administration, the recommended daily dose of valproic acid is 5-10 mg / kg. For intravenous infusion, the recommended dose of valproic acid is 0.5Ц1 mg / kg / h.
When switching from oral administration to intravenous administration, the dose is not changed, the first intravenous administration is recommended 12 hours after the last oral administration. The introduction of a solution for injection should be replaced by taking the drug inside, as soon as the patient's condition allows it. The first oral administration is also recommended 12 hours after the last injection.
If it is necessary to quickly achieve and maintain a high plasma concentration, the following approach is recommended: intravenous administration of 15 mg / kg over 5 minutes, after 30 minutes, start the infusion at a rate of 1 mg / kg / h with constant monitoring of the concentration until a plasma level of about 75 is reached. ?g / ml.
The maximum daily dose of the drug should not exceed 2500 mg.
Average daily doses are 20 mg / kg in adults and elderly patients, 25 mg / kg in adolescents, 30 mg / kg in children.
As an infusion solution for KonvulexЃ, isotonic sodium chloride solution, 5% dextrose solution, Ringer's solution can be used. The prepared solution for infusion can be used within 24 hours, the unused volume of the solution is destroyed. If other drugs are also used intravenously, KonvulexЃ must be administered via a separate infusion system.
| Solution for intravenous administration 100 mg / ml | 5 ml (1 amp.) |
| active substance: | |
| sodium valproate | 500 mg |
| equivalent of valproic acid 433.9 mg | |
| excipients: sodium hydroxide - 117 mg; sodium hydrogen phosphate dodecahydrate - 71.8 mg, water for injection - up to 5 ml |
hypersensitivity to valproic acid and its salts or drug components;
liver failure;
acute and chronic hepatitis;
dysfunction of the pancreas;
porphyria;
hemorrhagic diathesis;
severe thrombocytopenia;
combination with mefloquine, St. John's wort, lamotrigine;
disorders of urea metabolism (including family history);
lactation period.
With caution: children - when treated with several antiepileptic drugs; children and adolescents with multiple concomitant diseases and severe seizures; impaired renal function; patients with anamnestic data on liver and pancreas diseases; oppression of bone marrow hematopoiesis (leukopenia, anemia, thrombocytopenia); congenital enzymopathies; organic brain damage; hypoproteinemia; children's age (up to 3 years old); pregnancy (especially the first trimester).